BioMarin Pharmaceuticals
BMRN
560 hedge funds and large institutions have $13.7B invested in BioMarin Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 196 increasing their positions, 196 reducing their positions, and 68 closing their positions.
65% more call options, than puts
Call options by funds: $116M | Put options by funds: $70.2M
18% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 68
1% more funds holding
Funds holding: 556 → 560 (+4)
0.21% more ownership
Funds ownership: 96.54% → 96.75% (+0.21%)
0% more repeat investments, than reductions
Existing positions increased: 196 | Existing positions reduced: 196
13% less capital invested
Capital invested by funds: $15.6B → $13.7B (-$1.97B)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$226M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$73.8M |
| 3 |
O
OrbiMed
New York
|
+$65.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$61.3M |
| 5 |
HM
HealthCor Management
New York
|
+$51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$275M |
| 2 |
ClearBridge Investments
New York
|
-$264M |
| 3 |
PA
Perceptive Advisors
New York
|
-$104M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$101M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$43.6M |
BMRN Hedge Fund Activity: Q1 2022 in Review
560 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2022, worth a combined $13.7B — down 13% from $15.6B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new BMRN positions and 68 closed out — a net gain of 12 holders — while 196 added to existing stakes and 196 trimmed.
The largest buyer was UBS Group, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $275M.
- 560 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2022, up from 556 in Q4 2021.
- Funds reported $13.7B of BioMarin Pharmaceuticals stock for Q1 2022, down 13% quarter-over-quarter.
- 80 funds opened new BioMarin Pharmaceuticals positions in Q1 2022 and 68 closed out, a net change of +12 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2022 was UBS Group, an estimated $226M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2022 was Capital Research Global Investors, an estimated $275M sold.
Based on aggregated 13F filings for Q1 2022.